Skip to main content

Parliamentary debates and questions

S5W-09931: Jackson Carlaw (Eastwood)

Scottish Conservative and Unionist Party

Date lodged: 23 June 2017

To ask the Scottish Government what recent (a) discussions it has had with and (b) advice it has received from (i) the Scottish Medicines Consortium and (ii) other bodies regarding the drug, Orkambi, being made available on the NHS for the treatment of cystic fibrosis.

Answered by: Shona Robison 19 July 2017

Decisions made by the Scottish Medicines Consortium (SMC) are independent of Ministers and Parliament and are based on clinical and cost-effectiveness at a national population level for all Scotland.

The SMC did not accept Orkambi® for routine use in Scotland in May 2016 because the submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient.

I have written to the manufacturer of Orkambi® to encourage them to undertake discussions with colleagues in National Health Services Scotland (NSS) and I understand those discussions are underway. I hope as part of these discussions the manufacturer can make their best offer on price and indicate they will re-submit an application for Orkambi® to the SMC.